So far, 2 leading treatments have fizzled. But Orexigen hopes for more success with its new Contrave.
Companies in diabetes treatment, weight management and weight-loss drugs could see see huge growth.
Under Armour is upgraded to 'outperform,' and First Solar is downgraded to 'underperform.'
Vivus shares dropped after it reported weaker-than-expected sales of its weight loss drug.
Analyst predicts it will take time, however, before Qsymia records meaningful revenue.
Companies are trying to use America's weight to their advantage.
An analyst says the weight-loss drug Qsymia can't live up to investors' expectations.
VIDEO ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
It's the second-biggest shopping season of the year, although the total amount spent is expected to drop from last year.
MONEY & POLITICS
MUST-SEE ON MSN
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'